977P - Is chemotherapy worthwhile in patients with FIGO stage 1B, lymph nodes negative, grade 3 endometrial cancer?

Date 09 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Endometrial Cancer
Gynaecologic Malignancies
Presenter Caterina Fontanella
Citation Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372
Authors C. Fontanella1, S. Lepori1, A. Barcellini1, G. Maltese1, C. Andreetta2, E. Tripodi1, F. Martinelli1, A. Cerrotta1, G. Bogani1, A. Ditto1, M. Signorelli1, C. Scaffa1, C. Sacco3, F. Raspagliesi1, D. Lorusso1
  • 1Gynecologic Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2Department Of Oncology, University Hospital of Udine, 33100 - Udine/IT
  • 3Department Of Oncology, AOU Santa Maria della Misericordia, 33100 - Udine/IT

Abstract

Background

FIGO stage 1b endometrial cancer represents a major treatment challenge and standard of care is still unclear.

Methods

From March 1996 to March 2016, we retrospectively collected patients diagnosed with endometrial cancer stage Ib (invasion ≥ 50% of the myometrium, 2009 FIGO staging), lymph nodes negative after lymphadenectomy, and grade 3. We performed descriptive analysis and Kaplan Meier test using SPSS 20.0.

Results

Overall, 39 consecutive patients have been collected (28 at the National Cancer Institute of Milan and 11 at the University Hospital of Udine). Median age was 65.8 years (range 35.6-84.9). Endometrioid adenocarcinoma was diagnosed in 32 patients (82.1%), 4 serous adenocarcinoma (10.3%), 2 papillary serous adenocarcinoma (5.1%), and 1 clear cell adenocarcinoma (2.6%). Taking into account only endometrioid histotype, 23 patients received adjuvant radiotherapy (RT): 13 patients (40.6%) received brachyRT, 7 patients (21.8%) received external RT, 3 patients (9.4%) received both; 13 patients underwent platinum-based adjuvant chemotherapy (CT): 7 patients only CT, 2 patients external RT followed by CT and 2 patients brachyRT followed by CT. After a median follow up of 45.8 months (range 27.3 -236.8), median disease-free survival was 23.3 months (range 4.7-157.4); 7 patients (21.9%) experienced disease relapse and 5 patients (15.6%) died due to endometrial cancer. Relapse rate was 21.7% in patients who received RT versus 22.2% who did not. To note, relapse rate was only 9.1% in patients who received CT versus 28.6% in patients who did not.

Conclusions

According to our study, patients with stage 1b, node negative, grade 3 endometrioid endometrial cancer seems to derive a great benefit from adjuvant chemotherapy. This data needs to be further investigated in a large prospective clinical trial.

Clinical trial identification

Legal entity responsible for the study

Department of Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Funding

None

Disclosure

All authors have declared no conflicts of interest.